ACTU Actuate Therapeutics Inc
USHealthcareAs of 2026-07-09 16:00
Why ACTU matters now
Actuate Therapeutics Inc (ACTU) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.23 with -7.52% on the session and $29.4M in market capitalization; recent performance reads 1-month -13.75% and YTD -66.18%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.6M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -39.9%.
The latest indexable market news headline is "Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $21.00; recent insider activity includes Fletcher Aaron G.L. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.87
P/S
0.00
EV/EBITDA
-1.94
DCF Value
$0.54
FCF Yield
-39.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-430.9%
ROA
-241.7%
ROIC
-521.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.6M | $-0.24 |
| Q4 2025 | $0.00 | $-4.6M | $-0.20 |
| FY 2025 | $0.00 | $-22.2M | $-1.06 |
| Q3 2025 | $0.00 | $-5.4M | $-0.25 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.00
Target (Median)
$21.00
Target Range
$21.00 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.53
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.